A Decade of Innovation in Breast Cancer (2015-2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives.

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260313 A Decade of Innovation in Breast Cancer (2015-2025): A Comprehensive Review of Clinical Trials, Targeted Therapies and Molecular Perspectives. Klaudia Dynarowicz, Dorota Bartusik-Aebisher, Sara Czech, Aleksandra Kawczyk-Krupka, David Aebisher The past decade has witnessed an unprecedented transformation in breast cancer management, driven by parallel advances in targeted therapies, immunomodulation, drug-delivery technologies, and molecular diagnostic tools. This review summarizes the key achievements of 2015-2025, encompassing all major biological subtypes of breast cancer as well as technological innovations with substantial clinical relevance. In hormone receptor-positive (HR+)/HER2- disease, the integration of CDK4/6 inhibitors, modulators of the PI3K/AKT/mTOR pathway, oral Selective Estrogen Receptor Degraders (SERDs), and real-time monitoring of Estrogen Receptor 1 (ESR1) mutations has enabled clinicians to overcome endocrine resistance and dynamically tailor treatment based on evolving molecular alterations detected in circulating biomarkers...